Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced ...

Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and ...

Palisade Bio (PALI) stock soared 150% Monday in the wake of news that it has cancelled a proposed offering and plans to conduct a reverse stock split instead. Read more here.

Palisade Bio's stock saw a surge in volume, trading at 26.97M shares, far exceeding its 107.68k average, with no news cited for the rise. Phase 1 study shows PALI-2108 is safe at 15mg-150mg doses ...

Palisade Bio has ended development of its lead and only drug in one of two potential indications after it ... Palisade's stock collapses as sole asset flunks phase 2 GI trial in post-surgery patients.

Palisade Bio Inc.’s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade ...

The reverse stock split was approved by Palisade Bio’s stockholders at the special meeting of stockholders held on October 4, 2022. The reverse stock split is primarily intended to increase the ...

Carlsbad, CA, April 03, 2024-- Palisade Bio, Inc.,, ... The reverse stock split was approved by Palisade Bio’s stockholders at the virtual special meeting of stockholders held on March 25, 2024.